Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
One new option listing and one option delisting on February 23rd » 08:30
02/23/21
02/23
08:30
02/23/21
08:30
SEEL

Seelos Therapeutics

$3.33 /

-0.41 (-10.96%)

, ZAGG

Zagg

$4.29 /

+0.015 (+0.35%)

New option listings for…

New option listings for February 23rd include Seelos Therapeutics Inc (SEEL). Option delistings effective February 23rd include ZAGG Inc (ZAGG).

ShowHide Related Items >><<
ZAGG Zagg
$4.29 /

+0.015 (+0.35%)

SEEL Seelos Therapeutics
$3.33 /

-0.41 (-10.96%)

SEEL Seelos Therapeutics
$3.33 /

-0.41 (-10.96%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
ZAGG Zagg
$4.29 /

+0.015 (+0.35%)

12/14/20 DA Davidson
Zagg downgraded to Neutral from Buy at DA Davidson
12/14/20 DA Davidson
Zagg downgraded to Neutral from Buy at DA Davidson
08/05/20 Ladenburg
Zagg price target raised to $7.75 from $6 at Ladenburg
03/12/20 DA Davidson
Zagg price target lowered to $9 from $17 at DA Davidson
  • 26
    Jan
  • 12
    Mar
SEEL Seelos Therapeutics
$3.33 /

-0.41 (-10.96%)

Hot Stocks
Seelos Therapeutics amends agreement to repurchase royalties for SLS-002 » 07:07
02/18/21
02/18
07:07
02/18/21
07:07
SEEL

Seelos Therapeutics

$3.83 /

-0.17 (-4.25%)

Seelos Therapeutics…

Seelos Therapeutics announced an amendment of the agreement with Vyera Pharmaceuticals for the development of SLS-002 - intranasal racemic ketamine - to repurchase in cash a significant portion of the royalties payable on any future net sales of SLS-002. On March 6, 2018, Seelos entered into an asset purchase agreement with Vyera to acquire the assets and liabilities of Vyera's intranasal racemic ketamine program, which Seelos now calls SLS-002. Seelos agreed to pay a mid-teens percentage royalty on any future net sales of SLS-002. Under this amendment, for additional cash payments, Seelos has agreed to repurchase 9% of the future royalties and reduce its royalty obligations to a mid-single digit percentage on any future net sales of SLS-002. Seelos has begun dosing patients in Part A of its Proof-of-Concept study, which is a 16-patient, open-label cohort, using 90mg of SLS-002 in patients who are imminently suicidal. Part A of the Proof-of-Concept study precedes Part B, which is a registrational double blind placebo-controlled trial.

ShowHide Related Items >><<
SEEL Seelos Therapeutics
$3.83 /

-0.17 (-4.25%)

SEEL Seelos Therapeutics
$3.83 /

-0.17 (-4.25%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
  • 26
    Jan
  • 12
    Mar
SEEL Seelos Therapeutics
$3.83 /

-0.17 (-4.25%)

Over a month ago
Hot Stocks
Seelos Therapeutics receives patent covering SLS-005 in Australia » 08:04
01/29/21
01/29
08:04
01/29/21
08:04
SEEL

Seelos Therapeutics

$2.24 /

+0.055 (+2.52%)

Seelos Therapeutics…

Seelos Therapeutics announced that it has been granted a patent from the Australian Patent Office covering SLS-005 titled: "Treatment of Protein Aggregation Myopathic and Neurodegenerative Diseases by Parenteral Administration of Trehalose". The issued patent covers a method for treating a disease associated with abnormal protein aggregation and/or inclusion body formation in myocytes, neurons, extracellular compartments, or alleviating at least one symptom associated therewith, in a human subject in need thereof comprised of an intravenous administration of a therapeutically effective amount of a pharmaceutical formulation, with trehalose as the sole active ingredient, that complies with other parameters regarding the formulation characteristics and duration of intravenous administration, as described in the patent application.

ShowHide Related Items >><<
SEEL Seelos Therapeutics
$2.24 /

+0.055 (+2.52%)

SEEL Seelos Therapeutics
$2.24 /

+0.055 (+2.52%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
  • 26
    Jan
  • 12
    Mar
  • 11
    Feb
SEEL Seelos Therapeutics
$2.24 /

+0.055 (+2.52%)

Syndicate
Seelos Therapeutics 15.244M share Spot Secondary priced at $2.05 » 08:32
01/26/21
01/26
08:32
01/26/21
08:32
SEEL

Seelos Therapeutics

$2.65 /

+0.07 (+2.71%)

The deal size was…

The deal size was increased to $31.25M in common stock from $25M in common stock. BTIG acted as sole book running manager for the offering.

ShowHide Related Items >><<
SEEL Seelos Therapeutics
$2.65 /

+0.07 (+2.71%)

SEEL Seelos Therapeutics
$2.65 /

+0.07 (+2.71%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
  • 26
    Jan
  • 12
    Mar
  • 11
    Feb
SEEL Seelos Therapeutics
$2.65 /

+0.07 (+2.71%)

Conference/Events
Seelos Therapeutics management to meet virtually with Roth Capital » 04:55
01/26/21
01/26
04:55
01/26/21
04:55
SEEL

Seelos Therapeutics

$2.65 /

+0.07 (+2.71%)

Virtual Meetings to be…

Virtual Meetings to be held on January 25-26 hosted by Roth Capital.

ShowHide Related Items >><<
SEEL Seelos Therapeutics
$2.65 /

+0.07 (+2.71%)

SEEL Seelos Therapeutics
$2.65 /

+0.07 (+2.71%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
  • 26
    Jan
  • 12
    Mar
  • 11
    Feb
SEEL Seelos Therapeutics
$2.65 /

+0.07 (+2.71%)

On The Fly
Fly Intel: After-Hours Movers » 18:53
01/25/21
01/25
18:53
01/25/21
18:53
IPAR

Inter Parfums

$60.50 /

+1.41 (+2.39%)

, GGG

Graco

$74.74 /

-1.17 (-1.54%)

, FUL

H.B. Fuller

$50.80 /

-1.98 (-3.75%)

, WSFS

WSFS Financial

$46.04 /

-0.5 (-1.07%)

, HXL

Hexcel

$47.09 /

-1.235 (-2.56%)

, STLD

Steel Dynamics

$38.37 /

-0.35 (-0.90%)

, BDGE

Bridge Bancorp

$27.19 /

-0.08 (-0.29%)

, STAA

Staar Surgical

$89.69 /

-1.69 (-1.85%)

, IAC

IAC

$202.84 /

+1.83 (+0.91%)

, NBTX

Nanobiotix

$17.47 /

-1.25 (-6.68%)

, BCRX

BioCryst

$9.15 /

-0.06 (-0.65%)

, JJSF

J & J Snack Foods

$156.47 /

+3.58 (+2.34%)

, CR

Crane

$78.60 /

-2.15 (-2.66%)

, KRMD

Koru Medical

$5.13 /

-0.06 (-1.16%)

, QUMU

Qumu

$8.11 /

-0.32 (-3.80%)

, SEEL

Seelos Therapeutics

$2.65 /

+0.07 (+2.71%)

, CVAC

CureVac

$104.31 /

+2.31 (+2.26%)

, ASO

Academy Sports

$23.70 /

+1.28 (+5.71%)

Check out this evening's…

ShowHide Related Items >><<
WSFS WSFS Financial
$46.04 /

-0.5 (-1.07%)

STLD Steel Dynamics
$38.37 /

-0.35 (-0.90%)

STAA Staar Surgical
$89.69 /

-1.69 (-1.85%)

SEEL Seelos Therapeutics
$2.65 /

+0.07 (+2.71%)

NBTX Nanobiotix
$17.47 /

-1.25 (-6.68%)

KRMD Koru Medical
$5.13 /

-0.06 (-1.16%)

JJSF J & J Snack Foods
$156.47 /

+3.58 (+2.34%)

IPAR Inter Parfums
$60.50 /

+1.41 (+2.39%)

IAC IAC
$202.84 /

+1.83 (+0.91%)

HXL Hexcel
$47.09 /

-1.235 (-2.56%)

GGG Graco
$74.74 /

-1.17 (-1.54%)

FUL H.B. Fuller
$50.80 /

-1.98 (-3.75%)

CVAC CureVac
$104.31 /

+2.31 (+2.26%)

CR Crane
$78.60 /

-2.15 (-2.66%)

BDGE Bridge Bancorp
$27.19 /

-0.08 (-0.29%)

BCRX BioCryst
$9.15 /

-0.06 (-0.65%)

ASO Academy Sports
$23.70 /

+1.28 (+5.71%)

IPAR Inter Parfums
$60.50 /

+1.41 (+2.39%)

12/02/20 DA Davidson
Inter Parfums price target lowered to $50 from $55 at DA Davidson
11/11/20 DA Davidson
Inter Parfums price target raised to $55 from $39 at DA Davidson
11/11/20 Citi
Inter Parfums price target raised to $56 from $46 at Citi
08/12/20 BWS Financial
Inter Parfums upgraded to Buy from Neutral at BWS Financial
GGG Graco
$74.74 /

-1.17 (-1.54%)

01/19/21 Jefferies
Graco upgraded to Buy from Hold at Jefferies
10/23/20 RBC Capital
Graco price target raised to $72 from $65 at RBC Capital
10/16/20 Berenberg
Graco initiated with a Hold at Berenberg
08/11/20
Fly Intel: Top five analyst upgrades
FUL H.B. Fuller
$50.80 /

-1.98 (-3.75%)

01/04/21 Baird
H.B. Fuller upgraded to Outperform, added to 2021 top picks at Baird
01/04/21 Baird
H.B. Fuller upgraded to Outperform from Neutral at Baird
12/18/20
Fly Intel: Top five analyst upgrades
12/18/20 Citi
H.B. Fuller upgraded to Buy from Neutral at Citi
WSFS WSFS Financial
$46.04 /

-0.5 (-1.07%)

04/01/20 Keefe Bruyette
WSFS Financial upgraded to Outperform from Market Perform at Keefe Bruyette
HXL Hexcel
$47.09 /

-1.235 (-2.56%)

01/21/21 Credit Suisse
Hexcel downgraded to Underperform from Neutral at Credit Suisse
01/21/21 Credit Suisse
Hexcel downgraded to Underperform from Neutral at Credit Suisse
12/15/20 KeyBanc
Hexcel downgraded to Sector Weight at KeyBanc
12/14/20 KeyBanc
Hexcel downgraded to Sector Weight from Overweight at KeyBanc
STLD Steel Dynamics
$38.37 /

-0.35 (-0.90%)

12/09/20 Morgan Stanley
Steel Dynamics initiated with an Overweight at Morgan Stanley
10/21/20 BMO Capital
Steel Dynamics price target raised to $35 from $32 at BMO Capital
09/18/20 BMO Capital
Steel Dynamics price target raised to $32 from $29 at BMO Capital
07/29/20 Deutsche Bank
Steel Dynamics price target raised to $31 from $27 at Deutsche Bank
BDGE Bridge Bancorp
$27.19 /

-0.08 (-0.29%)

12/16/20 Boenning & Scattergood
Bridge Bancorp downgraded to Neutral from Outperform at Boenning & Scattergood
11/13/20 DA Davidson
Bridge Bancorp upgraded to Buy from Neutral at DA Davidson
STAA Staar Surgical
$89.69 /

-1.69 (-1.85%)

01/19/21 Benchmark
Staar Surgical downgraded to Hold on valuation at Benchmark
01/19/21 Benchmark
Staar Surgical downgraded to Hold from Buy at Benchmark
11/09/20 Canaccord
Staar Surgical price target raised to $84 from $70 at Canaccord
10/26/20 Sidoti
Staar Surgical downgraded to Neutral from Buy at Sidoti
IAC IAC
$202.84 /

+1.83 (+0.91%)

01/25/21 Piper Sandler
IAC price target raised to $240 from $211 at Piper Sandler
01/14/21 Deutsche Bank
IAC price target raised to $230 from $165 at Deutsche Bank
01/12/21 Piper Sandler
IAC price target raised to $211 from $205 at Piper Sandler
01/08/21 Goldman Sachs
Goldman Sachs sees IAC news as positive for MGM Resorts
NBTX Nanobiotix
$17.47 /

-1.25 (-6.68%)

01/05/21 Evercore ISI
Nanobiotix initiated with an Outperform at Evercore ISI
01/05/21 UBS
Nanobiotix initiated with a Buy at UBS
BCRX BioCryst
$9.15 /

-0.06 (-0.65%)

12/22/20 JMP Securities
BioCryst selloff today a buying opportunity, says JMP Securities
12/07/20 H.C. Wainwright
BioCryst price target raised to $14 from $13 at H.C. Wainwright
12/04/20 Piper Sandler
BioCryst receives on-time approval with 'clean' label, says Piper Sandler
11/23/20 Evercore ISI
BioCryst initiated with an Outperform at Evercore ISI
JJSF J & J Snack Foods
$156.47 /

+3.58 (+2.34%)

05/12/20 CL King
J & J Snack Foods upgraded to Buy from Neutral at CL King
CR Crane
$78.60 /

-2.15 (-2.66%)

01/07/21 Vertical Research
Crane upgraded to Buy with $97 price target at Vertical Research
01/07/21 DA Davidson
Crane cut to Neutral at DA Davidson on valuation
01/07/21 DA Davidson
Crane downgraded to Neutral from Buy at DA Davidson
10/07/20 DA Davidson
DA Davidson positive on Crane's Engineered Materials, PMT segments
KRMD Koru Medical
$5.13 /

-0.06 (-1.16%)

01/25/21 Piper Sandler
Koru Medical downgraded to Neutral from Overweight at Piper Sandler
11/04/20 Piper Sandler
Koru Medical earnings selloff a buying opportunity, says Piper Sandler
08/10/20 H.C. Wainwright
KORU Medical Systems initiated with a Buy at H.C. Wainwright
08/05/20 Piper Sandler
KORU Medical Systems price target raised to $14 from $12 at Piper Sandler
QUMU Qumu
$8.11 /

-0.32 (-3.80%)

07/15/20 Craig-Hallum
Qumu price target raised to $5 from $4 at Craig-Hallum
06/30/20 Craig-Hallum
Qumu upgraded to Buy at Craig-Hallum after merger agreement termination
06/30/20 Craig-Hallum
Qumu upgraded to Buy from Hold at Craig-Hallum
02/12/20
Qumu downgraded to Neutral from Buy at Dougherty
SEEL Seelos Therapeutics
$2.65 /

+0.07 (+2.71%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
CVAC CureVac
$104.31 /

+2.31 (+2.26%)

01/07/21 Morgan Stanley
CureVac COVID-19 deal provides 'sentiment boost' for Bayer, says Morgan Stanley
12/10/20 Credit Suisse
CureVac downgraded to Underperform on rising valuation at Credit Suisse
12/10/20 Credit Suisse
CureVac downgraded to Underperform from Neutral at Credit Suisse
11/02/20 Piper Sandler
CureVac's positive vaccine data bodes well for Arcturus's ARCT-021, says Piper
ASO Academy Sports
$23.70 /

+1.28 (+5.71%)

10/27/20
Fly Intel: Top five analyst initiations
10/27/20 UBS
Academy Sports initiated with a Buy at UBS
10/27/20 Credit Suisse
Academy Sports initiated with an Outperform at Credit Suisse
10/27/20 JPMorgan
Academy Sports initiated with an Overweight at JPMorgan
WSFS WSFS Financial
$46.04 /

-0.5 (-1.07%)

STLD Steel Dynamics
$38.37 /

-0.35 (-0.90%)

STAA Staar Surgical
$89.69 /

-1.69 (-1.85%)

QUMU Qumu
$8.11 /

-0.32 (-3.80%)

KRMD Koru Medical
$5.13 /

-0.06 (-1.16%)

JJSF J & J Snack Foods
$156.47 /

+3.58 (+2.34%)

IPAR Inter Parfums
$60.50 /

+1.41 (+2.39%)

IAC IAC
$202.84 /

+1.83 (+0.91%)

HXL Hexcel
$47.09 /

-1.235 (-2.56%)

GGG Graco
$74.74 /

-1.17 (-1.54%)

FUL H.B. Fuller
$50.80 /

-1.98 (-3.75%)

CR Crane
$78.60 /

-2.15 (-2.66%)

BDGE Bridge Bancorp
$27.19 /

-0.08 (-0.29%)

BCRX BioCryst
$9.15 /

-0.06 (-0.65%)

ASO Academy Sports
$23.70 /

+1.28 (+5.71%)

  • 28
    Jan
  • 26
    Jan
  • 27
    Jan
  • 28
    Jan
  • 20
    Jan
  • 11
    Dec
  • 02
    Oct
  • 14
    Aug
  • 19
    Jun
  • 28
    May
  • 12
    Mar
  • 11
    Feb
STLD Steel Dynamics
$38.37 /

-0.35 (-0.90%)

IAC IAC
$202.84 /

+1.83 (+0.91%)

HXL Hexcel
$47.09 /

-1.235 (-2.56%)

CVAC CureVac
$104.31 /

+2.31 (+2.26%)

QUMU Qumu
$8.11 /

-0.32 (-3.80%)

KRMD Koru Medical
$5.13 /

-0.06 (-1.16%)

IPAR Inter Parfums
$60.50 /

+1.41 (+2.39%)

IAC IAC
$202.84 /

+1.83 (+0.91%)

HXL Hexcel
$47.09 /

-1.235 (-2.56%)

FUL H.B. Fuller
$50.80 /

-1.98 (-3.75%)

CVAC CureVac
$104.31 /

+2.31 (+2.26%)

BCRX BioCryst
$9.15 /

-0.06 (-0.65%)

ASO Academy Sports
$23.70 /

+1.28 (+5.71%)

STLD Steel Dynamics
$38.37 /

-0.35 (-0.90%)

KRMD Koru Medical
$5.13 /

-0.06 (-1.16%)

FUL H.B. Fuller
$50.80 /

-1.98 (-3.75%)

CVAC CureVac
$104.31 /

+2.31 (+2.26%)

BCRX BioCryst
$9.15 /

-0.06 (-0.65%)

ASO Academy Sports
$23.70 /

+1.28 (+5.71%)

Syndicate
Seelos Therapeutics announces common stock offering, no amount given » 16:02
01/25/21
01/25
16:02
01/25/21
16:02
SEEL

Seelos Therapeutics

$2.59 /

+0.005 (+0.19%)

Seelos Therapeutics…

Seelos Therapeutics announced that it has commenced a proposed underwritten public offering of shares of common stock. Seelos intends to use a portion of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes and the remainder for general corporate purposes and to advance the development of its product candidates. BTIG is acting as the sole book-running manager for the offering.

ShowHide Related Items >><<
SEEL Seelos Therapeutics
$2.59 /

+0.005 (+0.19%)

SEEL Seelos Therapeutics
$2.59 /

+0.005 (+0.19%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
  • 12
    Mar
  • 11
    Feb
Conference/Events
Seelos Therapeutics management to meet virtually with Roth Capital » 04:55
01/25/21
01/25
04:55
01/25/21
04:55
SEEL

Seelos Therapeutics

$2.58 /

+0.47 (+22.27%)

Virtual Meetings to be…

Virtual Meetings to be held on January 25-26 hosted by Roth Capital.

ShowHide Related Items >><<
SEEL Seelos Therapeutics
$2.58 /

+0.47 (+22.27%)

SEEL Seelos Therapeutics
$2.58 /

+0.47 (+22.27%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
  • 12
    Mar
  • 11
    Feb
Hot Stocks
Seelos Therapeutics receives Notice of Allowance in Japan for SLS-005 » 09:02
01/22/21
01/22
09:02
01/22/21
09:02
SEEL

Seelos Therapeutics

$2.14 /

+0.3 (+16.30%)

Seelos Therapeutics has…

Seelos Therapeutics has received a Notice of Allowance from the Japanese Patent Office covering SLS-005. The allowed claims cover a pharmaceutical formulation comprised of trehalose for use in a method for treating or alleviating oculopharyngeal muscular dystrophy in a human subject. Trehalose is a low molecular weight disaccharide that crosses the blood brain barrier, stabilizes proteins, and activates autophagy which is the process that clears material from cells. In several animal models of diseases, associated with abnormal cellular protein aggregation or storage of pathologic material.

ShowHide Related Items >><<
SEEL Seelos Therapeutics
$2.14 /

+0.3 (+16.30%)

SEEL Seelos Therapeutics
$2.14 /

+0.3 (+16.30%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
  • 12
    Mar
  • 11
    Feb
Conference/Events
Seelos Therapeutics management to meet virtually with Roth Capital » 12:39
01/20/21
01/20
12:39
01/20/21
12:39
SEEL

Seelos Therapeutics

$1.71 /

-0.01 (-0.58%)

Virtual Meetings to be…

Virtual Meetings to be held on January 25-26 hosted by Roth Capital.

ShowHide Related Items >><<
SEEL Seelos Therapeutics
$1.71 /

-0.01 (-0.58%)

SEEL Seelos Therapeutics
$1.71 /

-0.01 (-0.58%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
  • 12
    Mar
  • 11
    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.